- Home
- CBNA vs BDTX Comparison
CBNA vs BDTX Comparison
Compare CBNA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- BDTX
- Stock Information
- Founded
- CBNA 2006
- BDTX 2014
- Country
- CBNA United States
- BDTX United States
- Employees
- CBNA N/A
- BDTX N/A
- Industry
- CBNA
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CBNA
- BDTX Health Care
- Exchange
- CBNA NYSE
- BDTX Nasdaq
- Market Cap
- CBNA 159.8M
- BDTX 132.5M
- IPO Year
- CBNA 2024
- BDTX 2020
- Fundamental
- Price
- CBNA $26.71
- BDTX $2.87
- Analyst Decision
- CBNA Buy
- BDTX Strong Buy
- Analyst Count
- CBNA 3
- BDTX 6
- Target Price
- CBNA $29.67
- BDTX $14.83
- AVG Volume (30 Days)
- CBNA 30.0K
- BDTX 1.2M
- Earning Date
- CBNA 08-15-2025
- BDTX 08-05-2025
- Dividend Yield
- CBNA N/A
- BDTX N/A
- EPS Growth
- CBNA 60.12
- BDTX N/A
- EPS
- CBNA 4.10
- BDTX 0.09
- Revenue
- CBNA $57,087,000.00
- BDTX $70,000,000.00
- Revenue This Year
- CBNA N/A
- BDTX N/A
- Revenue Next Year
- CBNA $17.50
- BDTX N/A
- P/E Ratio
- CBNA $6.50
- BDTX $32.58
- Revenue Growth
- CBNA 62.88
- BDTX N/A
- 52 Week Low
- CBNA $20.01
- BDTX $1.20
- 52 Week High
- CBNA $27.97
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- BDTX 68.91
- Support Level
- CBNA N/A
- BDTX $2.43
- Resistance Level
- CBNA N/A
- BDTX $2.72
- Average True Range (ATR)
- CBNA 0.00
- BDTX 0.18
- MACD
- CBNA 0.00
- BDTX 0.02
- Stochastic Oscillator
- CBNA 0.00
- BDTX 99.31
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.